4.31
Precedente Chiudi:
$4.38
Aprire:
$4.35
Volume 24 ore:
206.71K
Relative Volume:
0.29
Capitalizzazione di mercato:
$279.60M
Reddito:
$207.32M
Utile/perdita netta:
$-61.04M
Rapporto P/E:
-4.5004
EPS:
-0.9577
Flusso di cassa netto:
$-25.97M
1 W Prestazione:
+7.75%
1M Prestazione:
+8.29%
6M Prestazione:
+85.78%
1 anno Prestazione:
-19.81%
Treace Medical Concepts Inc Stock (TMCI) Company Profile
Nome
Treace Medical Concepts Inc
Settore
Industria
Telefono
(904) 373-5940
Indirizzo
100 PALMETTO PARK PLACE, PONTE VEDRA
Compare TMCI vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
TMCI
Treace Medical Concepts Inc
|
4.31 | 264.68M | 207.32M | -61.04M | -25.97M | -0.9577 |
|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Treace Medical Concepts Inc Stock (TMCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-02-04 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-12-31 | Iniziato | Lake Street | Buy |
| 2024-12-17 | Ripresa | JP Morgan | Neutral |
| 2024-05-16 | Downgrade | UBS | Buy → Neutral |
| 2024-05-08 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-05-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-05-08 | Downgrade | Stifel | Buy → Hold |
| 2024-05-08 | Downgrade | Truist | Buy → Hold |
| 2023-09-29 | Iniziato | UBS | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-04-11 | Iniziato | Stephens | Equal-Weight |
| 2022-05-12 | Iniziato | BTIG Research | Buy |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-18 | Iniziato | JP Morgan | Overweight |
| 2021-05-18 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-05-18 | Iniziato | SVB Leerink | Outperform |
| 2021-05-18 | Iniziato | Stifel | Buy |
Mostra tutto
Treace Medical Concepts Inc Borsa (TMCI) Ultime notizie
Treace Medical Concepts Inc (TMCI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TMCI|Treace Medical Concepts Inc|Price:4.060|Chg%:+0.060 - TradingKey
Treace Medical Concepts Inc (TMCI) Cash Flow - TradingKey
Treace Medical Concepts Inc - TradingKey
Treace Medical Concepts Inc (TMCI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Treace Medical Concepts, Inc. Revenue Breakdown – NASDAQ:TMCI - TradingView
Investors urged to act as law firm probes Treace Medical's board for possible breaches of duty. - Pluang
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Treace to Report Second Quarter 2026 Financial Results on August 7, 2026 - The Manila Times
Treace will discuss Q2 results live before markets open Aug. 7 - Stock Titan
TMCI|Treace Medical Concepts Inc|Price:4.000|Chg%:-0.050 - TradingKey
Treace Medical Concepts to Release Q2 2026 Financial Results - Intellectia AI
Treace Medical Concepts Lawsuit: Court Dismisses Investor Complaint Without Prejudice - TipRanks
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
Treace Medical Concepts (NASDAQ:TMCI) Given New $4.00 Price Target at Truist Financial - MarketBeat
Treace Medical Concepts Price Target Raised to $4.00/Share From $2.00 by Truist Securities - Moomoo
Truist Securities Adjusts Price Target on Treace Medical Concepts to $4 From $2, Maintains Hold Rating - marketscreener.com
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Short Interest Down 46.6% in June - MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Treace Medical Concepts, Inc. (TMCI) - Supply Chain Digital
Law firm investigates Treace Medical for alleged false statements affecting shareholders. - Pluang
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
3 Penny Stocks With Market Caps Under $900M To Watch - simplywall.st
TMCITreace Medical Concepts Inc Earnings - Finviz
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) dropped from Russell 2000 Index - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) added to Russell Microcap Index - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Treace Medica - The National Law Review
Treace Medical Concepts, Inc. (TMCI) Investigation: Bronstein, Ge - The National Law Review
Treace Medical Concepts, Inc.(NasdaqGS: TMCI) dropped from Russell 3000 Index - marketscreener.com
Levi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) InvestorsLead Plaintiff Deadline on June 10, 2025 - The National Law Review
Treace Medical Concepts Inc (TMCI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Analysts Are Updating Their Treace Medical Concepts, Inc. (NASDAQ:TMCI) Estimates After Its First-Quarter Results - 富途牛牛
Enterprise value to revenue forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Price to earnings forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Price to earnings forward of Treace Medical Concepts, Inc. – BOATS:TMCI - TradingView
Price to sales forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Enterprise value to EBITDA forward of Treace Medical Concepts, Inc. – NASDAQ:TMCI - TradingView
Enterprise value to EBITDA forward of Treace Medical Concepts, Inc. – BOATS:TMCI - TradingView
Treace Medical Concepts Inc (TMCI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Treace Medical Concepts (TMCI) Q3 2024 earnings summary - Quartr
Treace Medical Concepts (TMCI) Q2 2024 earnings summary - Quartr
Treace Medical Concepts (TMCI) Q1 2026 earnings summary - Quartr
Treace Medical Concepts (TMCI) Proxy filing Summary - Quartr
Treace Medical Concepts (TMCI) Sidoti Small-Cap Virtual Investor Conference Summary - Quartr
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System - GlobeNewswire
Treace Medical Concepts Inc (TMCI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Treace Medical Concepts Inc (TMCI) Institutional Confidence - TradingKey
Treace Medical Concepts Inc Azioni (TMCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Treace Medical Concepts Inc Azioni (TMCI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Treace John T. | Chief Executive Officer |
Jun 11 '26 |
Buy |
4.04 |
22,887 |
92,541 |
7,376,150 |
| Treace John T. | Chief Executive Officer |
Jun 01 '26 |
Buy |
3.56 |
50,000 |
177,915 |
7,323,833 |
| Treace John T. | Chief Executive Officer |
May 28 '26 |
Buy |
3.02 |
61,202 |
184,824 |
7,273,833 |
| Treace John T. | Chief Executive Officer |
May 27 '26 |
Buy |
2.87 |
49,810 |
143,189 |
7,212,631 |
| Treace John T. | Chief Executive Officer |
May 26 '26 |
Buy |
2.79 |
4,508 |
12,576 |
7,162,821 |
| Treace John T. | Chief Executive Officer |
May 14 '26 |
Buy |
2.62 |
61,750 |
161,495 |
7,158,313 |
| Treace John T. | Chief Executive Officer |
May 13 '26 |
Buy |
2.46 |
49,013 |
120,533 |
7,096,563 |
| Treace John T. | Chief Executive Officer |
May 12 '26 |
Buy |
2.17 |
43,000 |
93,478 |
7,047,550 |
| Scanlan Sean F. | Chief Innovation Officer |
Feb 10 '26 |
Option Exercise |
1.05 |
16,875 |
17,719 |
706,474 |
| Scanlan Sean F. | Chief Innovation Officer |
Jan 21 '26 |
Option Exercise |
0.72 |
53,500 |
38,520 |
427,099 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):